Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.

PURPOSE: We defined the efficacy of radiotherapy for the treatment of high grade (Gleason scores 8 to 10) adenocarcinoma of the prostate. MATERIALS AND METHODS: A total of 50 patients underwent radiotherapy with curative intent for clinically localized prostate cancer with Gleason scores of 8 to 10 at 1 of 4 facilities affiliated with the University of California San Francisco. Patients were considered to have biochemical failure if they had a significant increase in prostate specific antigen (PSA) of 0.5 ng./ml. per year, an increase in PSA to greater than 1.0 ng./ml. or a positive biopsy. RESULTS: Among the 50 patients median PSA was 22.7 ng./ml. (range 1.3 to 93.4). Tumors were clinical stage T1 or T2 in 46% of the cases and stage T3 or T4 in 54%. The overall actuarial probability of freedom from biochemical failure at 4 years was 23%. In a multivariate analysis including all patients pretreatment PSA was the only predictor of PSA failure, with 64% free of progression if the pretreatment PSA was 10 ng./ml. or less compared to only 16% at 3 years if PSA was more than 10 ng./ml. (p = 0.01). In a multivariate analysis restricted to patients with PSA less than 20 ng./ml. 83% of those treated to more than 71 Gy. were free of progression compared to 0% for those treated to less than 71 Gy. (p = 0.03). In a multivariate analysis PSA 10 ng./ml. or less (related risk 11.4, p = 0.02), T stage 1 or 2 (relative risk 3.8, p = 0.05) and radiation dose more than 71 Gy. (relative risk 4.0, p = 0.06) were associated with a favorable outcome. CONCLUSIONS: At 4 years the freedom from PSA failure following radiotherapy for high grade prostate cancer was comparable to previously reported surgical series. The high failure rate among patients with PSA greater than 20 ng./ml. suggests that these patients should be considered for investigational approaches. The apparent improvement in freedom from progression with the use of higher doses provides reason for optimism.

Bilateral arcs using "averaged beam's eye views": a simplified technique for delivering 3-D based conformal radiotherapy.

The purpose of this study is to describe a conformal radiotherapy technique for treating only the prostate with bilateral 120 degrees arcs using "averaged beams-eye-views" (A-BEV). For this study a CT scan from a patient with a large prostate but with a low risk for seminal vesicle involvement was chosen for comparing several different treatment techniques. Dose volume histograms (DVHs) of the prostate, femoral heads, bladder, and rectum were compared for plans using "standard" bilateral 120 degree unblocked arcs (8 x 8 and 9 x 9 cm), similar sized arcs with "generic" (small corner) blocks applied, arcs using hand drawn "semi-conformal" blocks added, and arcs using the A-BEV. The A-BEV was generated by averaging the shapes of fixed lateral and oblique BEVs from a six-field plan. These arc techniques were compared to four-field conformal (4-FC) and six-field conformal (6-FC) techniques. The addition of generic corner blocks to a 9 x 9 field resulted in a more favorable dose distribution than using open unblocked 9 x 9 arcs. The technique employing the A-BEV resulted in an improvement in the DVHs compared to other arc techniques and to 4-FC techniques. The dose volume histograms associated with using this technique approached those associated with using a 6-FC technique. Treating only the prostate with blocked arcs generated using an A-BEV results in an improved dose distribution compared to unblocked arcs and 4-FC techniques. This blocked arc technique also results in a DVH that is comparable to using a more complex 6-FC technique. Blocks that are drawn on manually reduce the dose to the surrounding normal tissues but are associated with a greater risk of underdosing the target volume. This problem is diminished when computer generated conformal blocks are used.

Complications of cobalt plaque therapy of choroidal malanomas.

We treated a small series of patients with choroidal malanomas with radioactive cobalt plaques. To assess the effectiveness of radiation, we performed radioactive phosphorus (32P) uptake determinations before and after treatment. The 32P results did not tumor destruction. In five of seven patients with posterior pole melanomas, radiation retinopathy developed after treatment with resultant decrease in vision.

Modification of radiation injury to normal tissues by chemotherapeutic agents.

The effects of several cancer chemotherapeutic agents on radiation damage to normal intestine, esophagus, and lung tissue were evaluated in LAF 1 mice using quantitative endpoints. In all tissues tested, actinomycin D increased injury and BCNU did not. In the intestine, adriamycin enhanced radiation damage more than any other agent. Bleomycin increased damage in the esophagus but not in the lung or intestine. Cyclophosphamide increased injury only in the lung, where vincristine caused minimal injury, and hydroxyurea, none. Only prednisolone caused significant radioprotection when given at the time of irradiation or at the time of expected death from pulmonary injury.